<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04104594</url>
  </required_header>
  <id_info>
    <org_study_id>19CH099</org_study_id>
    <secondary_id>2019-A01625-52</secondary_id>
    <nct_id>NCT04104594</nct_id>
  </id_info>
  <brief_title>Olfaction and Inflammation in Chronic Rhinosinusitis With Nasal Polyps</brief_title>
  <acronym>OIPN</acronym>
  <official_title>Olfaction and Inflammation in Chronic Rhinosinusitis With Nasal Polyps</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Impaired olfaction is one of the major complaints of patients with nasosinus polyposis, with
      nasal obstruction. In case of failure of medical treatment for patients with polyposis
      nasosinusal, they may use endoscopic surgery nasosinusal. Before surgery, 73% are hyposmic or
      anosmic, compared to 43% after surgery. Persistence of hyposmia or anosmia despite the
      removal of polyps can be explained by mechanisms inflammatory in the mucous membrane of the
      olfactory cleft. In addition, studies in mice have shown a degeneration of primary olfactory
      neurons at the level of the olfactory mucosa in connection with directly with TNF alpha, a
      pro-inflammatory molecule.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>expression rate of TNF-alpha in biopsies</measure>
    <time_frame>2 months</time_frame>
    <description>The main evaluation criterion is based on two variables: the expression rate of TNF-alpha in olfactory slit biopsies and the Sniffin Stick test score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sniffin Stick test score</measure>
    <time_frame>2 months</time_frame>
    <description>The main evaluation criterion is based on two variables: the expression rate of TNF-alpha in olfactory slit biopsies and the Sniffin Stick test score.
Sniffin Stick test score :
The final score, out of 48, is the sum of the olfactory threshold (out of 16), discrimination (out of 16) and identification (out of 16) scores.
Normal test values are defined as greater than the tenth percentile of the general population, so the test result is compared to reference values on a chart to determine whether the patient is normosmic, hyposmic or anosmic.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Olfactory Cleft Endoscopic Score</measure>
    <time_frame>2 months</time_frame>
    <description>5 endoscopic feature to be completed :
discharge : 0= none or scant clear/thin drainage (normal) ; 1= more abundant, thicker clear/white drainage (not normal but not purulent) ; 2= thicker, more abundant, discolored/purulent drainage.
polyps : 0= none ; 1= discrete polyps partially narrowing/blocking the olfactory cleft (&lt;50%) ; 2= discrete polyps completely narrowing/blocking the olfactory cleft (&gt;50%).
edema : 0= none ; 1= swelling partially narrowing/blocking the olfactory cleft (&lt;50%) ; 2= swelling completely narrowing/blocking the olfactory cleft (&gt;50%).
crusting : 0= none ; 1= mild ; 2= severe
scarring : 0= none ; 1= mild ; 2= severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>expression rate of TNF-alpha in polyps</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Nasal Polyps</condition>
  <condition>Chronic Rhinosinusitis With Nasal Polyps</condition>
  <condition>Olfaction Disorders</condition>
  <arm_group>
    <arm_group_label>patients with chronic rhinosinusitis with nasal polyps</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Sniffin Stick Test</intervention_name>
    <description>The test consists of odorous rods that are presented to the patient's nose. It consists of 3 parts different, with 3 sets of corresponding sticks: an olfactory threshold test, an olfactory discrimination test and an olfactory identification test.
The final score, out of 48, is the sum of the olfactory threshold, discrimination and identification scores. Normal test values are defined as greater than the tenth percentile of the general population, so the test result is compared to reference values on a chart to determine whether the patient is normosmic, hyposmic or anosmic.</description>
    <arm_group_label>patients with chronic rhinosinusitis with nasal polyps</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>numerical evaluation scale for olfaction</intervention_name>
    <description>numerical rating scale from 0 (no smell) to 10 (perfect smell)</description>
    <arm_group_label>patients with chronic rhinosinusitis with nasal polyps</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>numerical evaluation scale for nasal obstruction</intervention_name>
    <description>numerical rating scale from 0 (no freedom of the nasal passages) to 10 (maximum nasal freedom)</description>
    <arm_group_label>patients with chronic rhinosinusitis with nasal polyps</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nasal outcome test</intervention_name>
    <description>list of symptoms and social/emotional consequences of rhino-sinusitis. 16 questions that the patient must code from &quot;no problem&quot; to &quot;serious problem&quot; over the last 15 days</description>
    <arm_group_label>patients with chronic rhinosinusitis with nasal polyps</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with nasosinus polyposis requiring nasosinus surgery

          -  Patient affiliated or entitled to a social security

          -  signed consent

        Exclusion Criteria:

          -  Patients with nasosinus polyposis secondary to another disease

          -  Patients with hyposmia or anosmia prior to naso-sinus polyposis

          -  Patients with diagnosed neurodegenerative disease

          -  Patients who are mentally or physically unable to perform olfactory tests

          -  Patients on anti-TNF-alpha therapy, long-term oral corticosteroid therapy, or other
             immunomodulatory therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie GAVID, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie GAVID, MD</last_name>
    <phone>0477127794</phone>
    <phone_ext>+33</phone_ext>
    <email>marie.gavid@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ludovic WORD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Saint-Etienne</name>
      <address>
        <city>Saint-Ã‰tienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marie GAVID, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yann LELONGE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marc DUMOLLARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Michel PRADES, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TNF alpha</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
    <mesh_term>Olfaction Disorders</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Polyps</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

